King Pharmaceuticals KG Less: change in cash and cash equivalents held for sale
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept kg:IncreaseDecreaseInCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsHeldForSale.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's less: change in cash and cash equivalents held for sale.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's less: change in cash and cash equivalents held for sale?
- King Pharmaceuticals (KG) reported less: change in cash and cash equivalents held for sale of -$754K in Q1 2026.